ABX464: Phase IIa started

Abivax began a double-blind, placebo-controlled, Mauritian Phase IIa trial to evaluate 25, 50, 75, 100 and 150 mg oral ABX464 once daily or every 3 days for 2 weeks in about 80 treatment-naïve patient...